UBS Group’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $11.8M | Sell |
3,447,925
-1,634,258
| -32% | -$5.61M | ﹤0.01% | 2285 |
|
|
2025
Q1 | $11.3M | Buy |
5,082,183
+3,106,835
| +157% | +$6.93M | ﹤0.01% | 2241 |
|
|
2024
Q4 | $5.79M | Buy |
1,975,348
+1,953,603
| +8,984% | +$5.72M | ﹤0.01% | 2850 |
|
|
2024
Q3 | $56.5K | Sell |
21,745
-73,246
| -77% | -$190K | ﹤0.01% | 5534 |
|
|
2024
Q2 | $281K | Sell |
94,991
-6,984
| -7% | -$20.7K | ﹤0.01% | 4325 |
|
|
2024
Q1 | $462K | Buy |
101,975
+99,475
| +3,979% | +$451K | ﹤0.01% | 4158 |
|
|
2023
Q4 | $14.3K | Buy |
+2,500
| New | +$14.3K | ﹤0.01% | 6080 |
|
|
2023
Q3 | – | Sell |
-13,366
| Closed | -$86.3K | – | 8251 |
|
|
2023
Q2 | $86.3K | Sell |
13,366
-53,532
| -80% | -$346K | ﹤0.01% | 5079 |
|
|
2023
Q1 | $504K | Buy |
66,898
+22,652
| +51% | +$171K | ﹤0.01% | 3699 |
|
|
2022
Q4 | $448K | Sell |
44,246
-50,592
| -53% | -$512K | ﹤0.01% | 3786 |
|
|
2022
Q3 | $938K | Buy |
94,838
+53,483
| +129% | +$529K | ﹤0.01% | 2894 |
|
|
2022
Q2 | $440K | Sell |
41,355
-21,070
| -34% | -$224K | ﹤0.01% | 3425 |
|
|
2022
Q1 | $609K | Sell |
62,425
-16,766
| -21% | -$164K | ﹤0.01% | 3634 |
|
|
2021
Q4 | $1.13M | Buy |
79,191
+15,784
| +25% | +$226K | ﹤0.01% | 3345 |
|
|
2021
Q3 | $1.27M | Buy |
63,407
+22,389
| +55% | +$448K | ﹤0.01% | 3077 |
|
|
2021
Q2 | $902K | Buy |
41,018
+37,949
| +1,237% | +$835K | ﹤0.01% | 3331 |
|
|
2021
Q1 | $104K | Buy |
3,069
+3,061
| +38,263% | +$104K | ﹤0.01% | 4945 |
|
|
2020
Q4 | $0 | Buy |
+8
| New | – | ﹤0.01% | 7308 |
|